Compare Vanguard S&P 500 ETF (VOO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 ETF vs GeneDx Holdings Corp — how do they compare? Vanguard S&P 500 ETF trades at $715.6 (market cap $1.80T), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Vanguard S&P 500 ETF is far larger — about 891.1× GeneDx Holdings Corp's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard S&P 500 ETF for 55 Days and GeneDx Holdings Corp for 19 Days on average.
| VOO | WGS | |
|---|---|---|
Market Cap | $1.80T | $2.02B |
Volume | 4,722,271 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $716.17 | $167.51 |
52-Week Low | $580.93 | $34.51 |
Typical Hold Time | 55 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOO trades at $715.68, up 0.18% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building despite short interest increasing 46.9% in September. Dividend yield remains modest with the next payment scheduled for September 30, 2026.
Outlook remains positive given S&P 500 exposure and historical resilience, though risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated short interest. The ETF's low-cost structure and diversification provide stability amid market volatility, making it suitable for core portfolio holdings.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
